Affluent Partners Holdings (1466) AI Stock Analysis

• Market Cap: $535.35M
• Dividend Yield: N/A
• Average Volume (3M): 304.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.31
• Revenue Growth: 152.54%
• EPS Growth: 87.07%
• Country: HK
• Employees: 84
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Luxury Goods
• EPS (TTM): <0.01
• Shares Outstanding: 892,254,100
• 10 Day Avg. Volume: 457,992
• 30 Day Avg. Volume: 304,341
• PEG Ratio: 0.30
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 7.57
• P/FCF Ratio: -61.23
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 6.05
• Enterprise Value/Gross Profit: 22.05
• Enterprise Value/Ebitda: -167.18
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: HK$0.50 ▼(-12.28% Downside)

The overall stock score is primarily impacted by financial performance challenges, including negative profitability and cash flow issues. Technical analysis shows a bearish trend, and valuation metrics are poor with a negative P/E ratio. The absence of earnings call and corporate events data limits further insights.

Affluent Partners Holdings Business Overview & Revenue Model

Company Description

Affluent Partners Holdings Limited, an investment holding company, engages in the purchase, process, design, production, assembly, trade, and wholesale distribution of pearls and jewelry products. It operates in two segments, Sales of Pearls and Jewellery Products, and Strategic Investment and Financial Services. The company is also involved in the real estate financial assets investment business. It has operations in Hong Kong, the United Kingdom, the United States, Japan, Europe, and the People's Republic of China. The company was formerly known as Man Sang Jewellery Holdings Limited and changed its name to Affluent Partners Holdings Limited in February 2017. Affluent Partners Holdings Limited was incorporated in 2014 and is based in Central, Hong Kong.

How the Company Makes Money

Affluent Partners Holdings generates revenue through multiple streams, primarily focusing on management fees, performance fees, and investment income. The company charges management fees based on the assets under management (AUM) for its investment funds, which provides a steady income stream. In addition, it earns performance fees when its investment returns exceed predefined benchmarks, aligning the company's interests with those of its investors. Furthermore, the company benefits from dividends and interest accrued from its investment portfolio, which includes public and private equities, fixed-income securities, and real estate holdings. Strategic partnerships with financial institutions and other investment firms also enhance its market reach and investment capabilities, contributing to the overall revenue growth and profitability of Affluent Partners Holdings.

Affluent Partners Holdings Financial Statement Overview

Summary

Affluent Partners Holdings shows strong revenue growth of 36.3%, but faces challenges with negative net profit and EBIT margins. The balance sheet is stable with a manageable debt-to-equity ratio, yet negative return on equity and cash flow issues indicate financial health concerns.

Income Statement

The company has shown significant revenue growth of 36.3% in the latest year, indicating strong sales performance. However, profitability remains a concern with a negative net profit margin and EBIT margin, reflecting ongoing operational challenges. The gross profit margin is moderate, suggesting some efficiency in cost management but not enough to offset other expenses.

Balance Sheet

The balance sheet shows a stable equity base with a debt-to-equity ratio of 0.72, which is manageable. However, the return on equity is negative, indicating that the company is not generating sufficient returns on its equity. The equity ratio is relatively healthy, suggesting a solid asset base.

Cash Flow

Cash flow analysis reveals a challenging situation with negative operating and free cash flows, indicating liquidity issues. The free cash flow growth is positive, but the overall cash flow position needs improvement to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	99.45M	53.68M	135.56M	86.88M	62.65M	43.32M
Gross Profit	27.29M	18.10M	41.99M	7.83M	10.99M	-8.62M
EBITDA	-3.60M	-6.32M	6.26M	11.13M	-9.73M	-45.45M
Net Income	-11.36M	-7.45M	-316.00K	8.73M	-15.46M	-51.78M
Balance Sheet
Total Assets	236.69M	196.80M	290.17M	99.85M	82.11M	91.77M
Cash, Cash Equivalents and Short-Term Investments	44.96M	37.88M	47.77M	41.26M	23.59M	24.42M
Total Debt	65.71M	51.19M	99.93M	2.76M	31.84M	31.56M
Total Liabilities	129.26M	84.01M	134.30M	21.51M	46.24M	45.82M
Stockholders Equity	86.63M	96.31M	139.28M	78.34M	35.87M	45.95M
Cash Flow
Free Cash Flow	-15.03M	-6.64M	-32.97M	-21.55M	1.06M	-16.21M
Operating Cash Flow	-14.47M	-6.46M	-30.53M	-21.52M	1.11M	-16.18M
Investing Cash Flow	4.28M	4.74M	-846.00K	35.30M	-60.00K	138.00K
Financing Cash Flow	18.45M	819.00K	41.41M	3.70M	-1.72M	6.77M

Affluent Partners Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.57
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1466, the sentiment is Neutral. The current price of 0.57 is above the 20-day moving average (MA) of 0.55, above the 50-day MA of 0.54, and below the 200-day MA of 0.61, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 53.49 is Neutral, neither overbought nor oversold. The STOCH value of 47.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1466.

Affluent Partners Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0280	73 Outperform	HK$472.84M	5.36	11.22%	10.37%	14.24%	3.63%
0398	70 Outperform	HK$1.70B	8.48	11.32%	10.08%	-5.19%	-19.96%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
0789	60 Neutral	HK$628.88M	75.40	5.25%	―	111.72%	1.61%
3389	49 Neutral	$515.27M	-13.00	-1.15%	―	-41.44%	-209.76%
1466	46 Neutral	$535.35M	-400.00	-0.25%	―	152.54%	87.07%
1856	44 Neutral	HK$655.67M	-10.19	-51.81%	―	-20.65%	-616.18%

Affluent Partners Holdings Corporate Events

Baijin Life Science Holdings Updates on Share Subscription Proceeds

Baijin Life Science Holdings Limited has announced a supplemental update regarding the subscription of new shares under a general mandate. The company plans to allocate 60% of the net proceeds, approximately HK$11.5 million, towards repaying various borrowings by March 2026, and the remaining 40%, approximately HK$7.6 million, will be used as general working capital by September 2026. This strategic move aims to reduce interest expenses without impacting the company’s cash position, benefiting the company and its shareholders. New investors, including Mr. Liu Weidong, Ms. Zhou Suya, and Ms. Wang Huiqin, have subscribed to these shares, with no prior business relationships with the company.

The most recent analyst rating on (HK:1466) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.

Baijin Life Science Strengthens Financial Position with Bond Conversion

Baijin Life Science Holdings Limited has announced the conversion of a convertible bond worth HK$31,500,000 into shares, leading to a change in its shareholding structure. This conversion will result in the cancellation of the bond, reducing the company’s liabilities and strengthening its balance sheet, thereby enhancing its financial position and enabling better resource allocation for future business development.

The most recent analyst rating on (HK:1466) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.

Baijin Life Science Approves Key Resolutions at AGM

Baijin Life Science Holdings Limited, a company incorporated in the Cayman Islands, held its Annual General Meeting on 30 September 2025. All proposed resolutions, including the re-election of directors and the authorization for share issuance and repurchase, were unanimously approved by shareholders. The meeting saw full attendance from the board, highlighting the company’s commitment to governance and strategic direction.

The most recent analyst rating on (HK:1466) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.

Affluent Partners Holdings Announces New Share Subscription

Affluent Partners Holdings, under the name Baijin Life Science Holdings Limited, announced the subscription of 40,000,000 new shares at HK$0.48 per share, representing approximately 5.18% of its existing issued share capital. This move is part of a general mandate and involves three independent individual investors, with no inter-conditional agreements among them. The subscription aims to enhance the company’s capital base, although completion is subject to certain conditions.

The most recent analyst rating on (HK:1466) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.

Baijin Life Science Holdings Announces 2025 AGM and Share Issuance Plans

Baijin Life Science Holdings Limited has announced its 2025 Annual General Meeting, which will take place on September 30, 2025, in Hong Kong. The meeting will address ordinary business matters such as the approval of audited financial statements, the re-election of directors, and the re-appointment of the independent auditor. Additionally, a special resolution will be discussed to authorize the directors to issue additional shares and securities, potentially impacting the company’s capital structure and shareholder value.